#ASCO14 - Poster: Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo

CHICAGO, IL USA (UroToday.com) - Presented by Michael J. Morris,1 Yohann Loriot,2 Tomasz M. Beer,3 Celestia S. Higano,4 Andrew J. Armstrong,5 Cora N. Sternberg,6 Johann De Bono,7 Bertrand Tombal,8 Sarah B. Noonberg,9 Hank Mansbach,9 Suman Bhattacharya,9 Frank Perabo,10 De Phung,10 and Dana E. Rathkopf1 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 morris PREVAIL thumb

1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY USA
2Institut Gustave Roussy, University of Paris Sud, Villejuif, France
3OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR USA
4Seattle Cancer Care Alliance, University of Washington, Seattle, WA USA
5Duke University Medical Center Duke Cancer Institute Divisions of Medical Oncology and Urology, Duke University, Durham, NC USA
6San Camillo and Forlanini Hospitals, Rome, Italy
7Royal Marsden Hospital and Institute of Cancer Research, London, UK
8Cliniques Universitaires Saint-Luc, Brussels, Belgium
9Medivation Inc., San Francisco, CA USA
10Astellas Pharma Global Development, Inc., Northbrook, IL USA

 

 

email news signup